Next-Generation Gene Therapy: Circio and Avenue Biosciences Forge Strategic Alliance to Revolutionize Protein Secretion
In a move set to redefine the boundaries of genetic medicine, biotechnology innovators Circio Holding and Avenue Biosciences have announced a high-stakes research collaboration. The partnership seeks to fuse their respective technological powerhouses—Circio’s circular RNA (circRNA) expression platform, circVec, and Avenue Biosciences’ proprietary protein engineering suite—to overcome one of the most persistent bottlenecks in gene therapy: the inefficient production and secretion of therapeutic proteins.
By targeting the cellular secretory pathway, the two companies aim to solve the “dosage dilemma” that has historically hampered the development of gene therapies for chronic and monogenic diseases. If successful, this synergy could pave the way for more potent, cost-effective, and durable treatments for conditions currently beyond the reach of conventional genetic medicine.
The Core Challenge: Why Protein Expression Matters
To understand the significance of this collaboration, one must first recognize the inherent limitations of current gene therapy modalities. Many existing viral-vector or lipid-nanoparticle-based therapies struggle with transient or insufficient protein expression. When a cell fails to produce enough therapeutic protein, clinicians are forced to increase dosage, which drives up manufacturing costs and exacerbates safety concerns.
The secretory pathway—the intricate biological machinery responsible for synthesizing, folding, and exporting proteins—remains an under-tapped frontier. Often, therapeutic proteins become “bottlenecked” inside the cell, failing to reach their target tissues or the circulatory system in therapeutic concentrations. Circio and Avenue are now positioning themselves to optimize this pipeline, ensuring that every molecule of genetic instruction leads to a tangible clinical result.
Chronology: Building the Synergy
The partnership follows a period of rapid evolution for both firms.
- Foundation Phase: Over the past few years, Circio Holding has been refining its circVec platform, a novel technology designed to produce circular RNA. Unlike linear mRNA, circular RNA is highly stable, resisting degradation and offering the potential for longer-term, more consistent protein expression.
- The Technological Pivot: Simultaneously, Avenue Biosciences has been perfecting a high-throughput screening platform capable of analyzing thousands of signal peptide-protein combinations. These signal peptides serve as the “zip codes” for proteins, dictating how effectively they are exported from the cell.
- The Agreement (Q4 2024): Recognizing that their technologies were inherently complementary, the leadership teams at Circio and Avenue began discussions regarding a formal research collaboration. The agreement, finalized in October 2024, establishes a roadmap for initial screening, in vitro validation, and eventual in vivo testing.
The Technological Synthesis
The core of this collaboration lies in the integration of two distinct, highly specialized scientific disciplines: RNA engineering and proteomic optimization.
H3: The CircVec Advantage
Circio’s circVec platform represents a shift away from traditional linear expression systems. By utilizing circular RNA, the company bypasses the rapid degradation processes that limit the half-life of standard mRNA therapies. Because circVec is designed for long-term, durable expression, it is particularly well-suited for chronic diseases where the patient requires a steady, sustained supply of a therapeutic protein.
H3: Avenue’s Signal Peptide Screening
Avenue Biosciences brings to the table a sophisticated protein engineering engine. The company’s technology focuses on signal peptides—short amino acid sequences that guide proteins through the cell’s secretory pathway. By screening thousands of these sequences against specific therapeutic proteins, Avenue can identify the precise configuration that maximizes cellular export.
When applied to the circVec platform, this technology acts as an "efficiency booster." While circVec provides the stable, long-lasting blueprint, Avenue’s signal peptides ensure that the resulting proteins are exported at maximum velocity, significantly increasing the total therapeutic yield per dose.
Official Perspectives: Leadership on the Future of Medicine
The executives involved in this partnership emphasize that this is not merely an incremental improvement but a fundamental change in how gene therapy will be manufactured and administered.
Dr. Tero-Pekka Alastalo, CEO of Avenue Biosciences, underscored the necessity of the collaboration in a recent statement:
"Many gene therapies are limited by insufficient protein expression, driving high doses, manufacturing complexity, and cost. The secretory pathway—the cellular machinery that produces and exports proteins—is a largely underutilized engineering opportunity. By combining Circio’s durable circular RNA expression with our technology, we aim to increase protein output per dose and ultimately help more patients benefit from life-changing genetic medicines."
Dr. Victor Levitsky, Chief Scientific Officer of Circio, echoed this sentiment, highlighting the strategic alignment of the two firms:
"A significant proportion of therapeutically relevant payloads for circVec are secreted proteins. With the Avenue platform, we will test how signal peptide optimization can enhance secretion of proteins and thereby open novel opportunities for the circVec platform in genetic and chronic disease. This collaboration is an important addition to our pre-clinical development strategy of testing circVec in multiple settings through R&D partnerships to broadly explore the range of therapeutic options available for our unique circular RNA expression technology."
Implications for the Future of Gene Therapy
The implications of this partnership extend far beyond the laboratory. If the combined platform proves successful, it could fundamentally alter the landscape of several medical sectors.
H3: Impact on Monogenic and Chronic Disease
For patients with monogenic diseases—disorders caused by the mutation of a single gene—this technology could mean the difference between a lifetime of frequent, invasive treatments and a one-time, long-acting therapy. For chronic conditions, such as metabolic or autoimmune disorders, the ability to maintain steady levels of therapeutic proteins in the blood could lead to unprecedented disease management.
H3: Reducing the Manufacturing Burden
One of the most significant barriers to the commercialization of genetic medicine is the "cost of goods." Current manufacturing processes for viral vectors are notoriously difficult and expensive to scale. By increasing the protein output per dose, the Circio-Avenue partnership offers a pathway to higher efficiency. If a lower dose can achieve the same therapeutic effect, the manufacturing footprint shrinks, making therapies more accessible to a wider patient population.
H3: Broadening the Therapeutic Payload
While many gene therapies are currently focused on replacing defective proteins, the circVec-Avenue collaboration opens the door to more complex payloads, including therapeutic antibodies. By engineering cells to act as "mini-factories" that efficiently pump out these antibodies, the researchers are effectively transforming the patient’s own tissues into long-term drug-delivery systems.
Looking Ahead: The Path to Clinical Validation
The collaboration is structured in a clear, phased approach to minimize risk and maximize scientific rigor.
- Initial Screening: Avenue Biosciences will take the lead on identifying the optimal signal peptides for a set of high-priority therapeutic proteins. This will involve high-throughput screening using their proprietary platform.
- In Vitro Testing: Once the optimal signal peptides are identified, they will be integrated into the circVec construct. Circio will then perform in vitro assays to measure the rate and quantity of protein secretion in laboratory-grown cell cultures.
- In Vivo Validation: The final phase will involve animal models, where the researchers will evaluate whether the enhanced secretion leads to improved clinical outcomes. This phase will be crucial in determining the pharmacokinetic profile of the combined technology.
While the collaboration is currently in the pre-clinical stage, the industry is watching closely. The convergence of RNA-based expression platforms and protein-secretion engineering represents a new frontier in synthetic biology. By addressing the bottleneck of the secretory pathway, Circio and Avenue Biosciences are not just optimizing existing treatments—they are building the infrastructure for the next generation of genetic medicine.
As the scientific community awaits the results of these initial screenings, one thing is clear: the integration of these synergistic technologies provides a promising template for future R&D. By focusing on the "machinery" of the cell rather than just the genetic instructions themselves, the partnership may well unlock a future where complex genetic and chronic diseases are treated with the precision, efficiency, and durability that patients have long deserved.
